Literature DB >> 31910107

Ultrasound-Guided Radiofrequency Ablation Versus Surgery for Low-Risk Papillary Thyroid Microcarcinoma: Results of Over 5 Years' Follow-Up.

Mingbo Zhang1, Ralph P Tufano2, Jonathon O Russell2, Ying Zhang1, Yan Zhang1, Zhi Qiao3, Yukun Luo1.   

Abstract

Background: Papillary thyroid microcarcinoma (PTMC) typically carries an excellent prognosis regardless of the treatment option pursued. Radiofrequency ablation (RFA) for thyroid disease has been utilized for benign lesions and in patients who are poor surgical candidates for thyroid cancers with compression symptoms, but the efficacy and limitations of RFA as first-line therapy for PTMC has not been described in adequate detail. The purpose of our study was to investigate RFA versus thyroidectomy in terms of efficacy, oncologic outcomes, quality of life, complications, and costs over a 5-year period of follow-up.
Methods: From January 2013 to November 2013, 174 consecutive patients with an isolated, solitary intrathyroidal PTMC were identified in a Chinese teaching hospital. Those with more aggressive or advanced PTMCs were not included. Ninety-four patients elected RFA and 80 patients elected surgery for treatment of these PTMC. Nodules were confirmed to be PTMC without an aggressive histological type by core needle biopsy in the RFA group and by final surgical pathology in the surgery group. The extent of surgery was decided based on patient preferences in consultation with the surgeons. Of all the patients, 58 (72.5%) underwent lobectomy, 22 (27.5%) underwent total thyroidectomy, and 53 (66.3%) underwent lymph node dissection. Pre- and post-treatment variables were compared between the two groups, including demographics, tumor characteristics, treatment, local tumor progression, lymph node metastasis, distant metastasis, local recurrence, complications, and quality-of-life findings.
Results: Patient-specific variables were similar between groups, as were oncologic outcomes after 5 years of follow-up. When compared with RFA, surgery took longer, had a longer hospitalization time, and was costlier (all p < 0.001). The surgery group had three complications, with 2 (2.5%) permanent recurrent laryngeal nerve injuries and 1 (1.3%) case of permanent hypoparathyroidism, while none was reported in the RFA group (p = 0.095). The surgery group had a lower post-treatment thyroid-related quality of life. Conclusions: For carefully selected low-risk intrathyroidal PTMC, RFA was not oncologically inferior to open surgery, and it was associated with a higher quality of life and lower overall costs.

Entities:  

Keywords:  microcarcinoma; papillary; radiofrequency ablation; thyroid; ultrasound

Mesh:

Year:  2020        PMID: 31910107     DOI: 10.1089/thy.2019.0147

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  33 in total

1.  Five-year follow-up results of thermal ablation for low-risk papillary thyroid microcarcinomas: systematic review and meta-analysis.

Authors:  Se Jin Cho; Sun Mi Baek; Dong Gyu Na; Kang Dae Lee; Young Kee Shong; Jung Hwan Baek
Journal:  Eur Radiol       Date:  2021-03-13       Impact factor: 5.315

2.  European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice Guideline for the Use of Minimally Invasive Treatments in Malignant Thyroid Lesions.

Authors:  Giovanni Mauri; Laszlo Hegedüs; Steven Bandula; Roberto Luigi Cazzato; Agnieszka Czarniecka; Oliver Dudeck; Laura Fugazzola; Romana Netea-Maier; Gilles Russ; Göran Wallin; Enrico Papini
Journal:  Eur Thyroid J       Date:  2021-05-25

3.  European Thyroid Association Survey on Use of Minimally Invasive Techniques for Thyroid Nodules.

Authors:  Laszlo Hegedüs; Andrea Frasoldati; Roberto Negro; Enrico Papini
Journal:  Eur Thyroid J       Date:  2020-03-27

Review 4.  Efficacy and safety of radiofrequency ablation in the treatment of low-risk papillary thyroid carcinoma: a review.

Authors:  Spyridon Ntelis; Dimitrios Linos
Journal:  Hormones (Athens)       Date:  2021-04-06       Impact factor: 2.885

5.  Radiofrequency ablation and thyroid nodules: updated systematic review.

Authors:  Haris Muhammad; Prasanna Santhanam; Jonathon O Russell
Journal:  Endocrine       Date:  2021-01-15       Impact factor: 3.633

6.  The Ablation of Thyroid Nodule's Afferent Arteries Before Radiofrequency Ablation: Preliminary Data.

Authors:  Chiara Offi; Sara Garberoglio; Giovanni Antonelli; Maria Grazia Esposito; Umberto Brancaccio; Claudia Misso; Edoardo D'Ambrosio; Daniela Pace; Stefano Spiezia
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-11       Impact factor: 5.555

Review 7.  Update of Radiofrequency Ablation for Treating Benign and Malignant Thyroid Nodules. The Future Is Now.

Authors:  Ralph P Tufano; Pia Pace-Asciak; Jonathon O Russell; Carlos Suárez; Gregory W Randolph; Fernando López; Ashok R Shaha; Antti Mäkitie; Juan P Rodrigo; Luiz Paulo Kowalski; Mark Zafereo; Peter Angelos; Alfio Ferlito
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-24       Impact factor: 5.555

8.  Occupational exposure and radiobiological risk from thyroid radioiodine therapy in Saudi Arabia.

Authors:  H I Al-Mohammed; A Sulieman; Fareed H Mayhoub; Hassan Salah; Celestino Lagarde; M Alkhorayef; Ali Aldhebaib; C Kappas; D A Bradley
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

9.  Clinical outcomes of radiofrequency ablation for multifocal papillary thyroid microcarcinoma versus unifocal papillary thyroid microcarcinoma: a propensity-matched cohort study.

Authors:  Lin Yan; Mingbo Zhang; Qing Song; Fang Xie; Yukun Luo
Journal:  Eur Radiol       Date:  2021-08-06       Impact factor: 5.315

10.  The Efficacy and Safety of Radiofrequency Ablation for Bilateral Papillary Thyroid Microcarcinoma.

Authors:  Lin Yan; Mingbo Zhang; Qing Song; Jing Xiao; Ying Zhang; Yukun Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-11       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.